Chemomab Therapeutics Ltd. (CMMB) stock
Close on Nov 12, 2026Market cap $10.07MP/E 1.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $10.07M
- P/E ratio
- 1.0
- Price to sales
- –
- Price to book
- 1.16
- Dividend yield
- –
- Free cash flow yield
- -110.56%
Fundamentals
- Net income
- -$9.00M
- EPS, diluted
- $0.02
- Free cash flow
- -$11.13M
- Book value per share
- $0.01
- Diluted shares
- 640M
Trading
- Previous close
- $1.35
- Open
- $1.35
- Day's range
- $1.35 – $1.49
- Volume
- 76,519
- Average volume (20 days)
- 58,047
- Beta (5 years)
- 1.45
- 52-week range
- $0.92 – $2.99
- RSI (14 days)
- 54.8
- Volatility (1 year)
- 95.0%
- Relative volume
- 0.62×
- WACC
- 12.1%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CMMB | S&P 500 | Difference | CMMB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.7% | -2.7% | +3.4 pts | ||
| 3 months | -27.1% | -1.7% | −25.3 pts | ||
| Year to date | -15.2% | +11.9% | −27.0 pts | ||
| 1 year | -47.8% | +12.0% | −59.7 pts | ||
| 3 years | -40.7% | +78.2% | −118.9 pts | -16.0% | +21.2% |
| 5 years | -96.4% | +73.2% | −169.6 pts | -48.6% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Chemomab Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Chemomab Therapeutics
Pharmaceutical Preparations
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for inflammatory and fibrotic disorders. The company designs targeted treatments centered primarily on antagonizing CCL24 signaling, a pathway that regulates inflammatory and fibrotic processes. Its pipeline is led by nebokitug (CM-101), an investigational drug candidate being evaluated in clinical studies for the treatment of primary sclerosing cholangitis and systemic sclerosis. Because nebokitug remains in clinical development, the company has no approved commercial products and does not currently generate revenue from commercial drug sales.
Company profile, executives and historyChemomab Therapeutics stock: common questions
What is Chemomab Therapeutics's stock price?
CMMB closed at $1.40 on Nov 12, 2026, up 3.70% on the day. Over the past 52 weeks it traded between $0.92 and $2.99.
What is Chemomab Therapeutics's market cap?
Chemomab Therapeutics was worth $10.07M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CMMB's P/E ratio?
CMMB trades at 1.0 times earnings, based on diluted earnings per share of $0.02 over fiscal 2025.
Does Chemomab Therapeutics pay a dividend?
No. Chemomab Therapeutics has not paid a cash dividend over the last twelve months.
How has CMMB stock performed over the past year?
Including dividends, CMMB returned -47.8% over the past year, against +12.0% for the S&P 500.
Who are Chemomab Therapeutics's competitors?
Companies most similar to Chemomab Therapeutics by business, industry and size include CRVS, ACRS, GRI, RNTX, EOCN.
See a number that looks wrong?